Catabasis Pharmaceuticals Inc (CATB): Deerfield Management Adds to Its Position

James E. Flynn‘s Deerfield Management recently filed a Form 13G with the SEC in which it reported holding 783,375 common shares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB), which amass 4.21% of the company’s outstanding common stock. This represents about a 21% increase to the fund’s stake, as it previously held 643,580 shares as of June 30, according to its 13F filing for the June 30 reporting period.

Catabasis Pharmaceuticals, as the name denotes it, is a clinical-stage biopharmaceutical company that works on the production of various therapeutics for treating inflammatory diseases and dyslipidemias. Over the past 12 months, the company’s stock has lost 22.9%. For the second quarter of 2016, Catabasis Pharmaceuticals disclosed a net loss of $9.45 million and a loss per share of $0.61, which compares to a net loss of $8.04 million and a loss per share of $8.07 for the corresponding quarter of 2015. Recently, Wedbush reiterated its ‘Outperform’ rating on Catabasis Pharmaceuticals’ stock, with a price target of $17.

The number of smart money managers within Insider Monkey’s database long Catabasis Pharmaceuticals (NASDAQ:CATB) stood at three at the end of June, same as at the end of the previous quarter. Among the bullish investors, aside from Deerfield Management, were Stephen DuBois’ Camber Capital Management, which held a position valued at $3.70 million, and D E Shaw, founded by David E. Shaw, which owned $52,000 worth of Catabasis Pharmaceuticals’ shares.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Page 1 of 12 – SEC Filing